<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Precision Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/precision-biosciences-inc</link>
<description>Latest news and press releases for Precision Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/precision-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355fca78dffbe2df0edbc9.webp</url>
<title>Precision Biosciences Inc</title>
<link>https://6ix.com/company/precision-biosciences-inc</link>
</image>
<item>
<title>Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-oral-presentation-at-the-american-society-of-gene-and-cell-therapy-asgct-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-oral-presentation-at-the-american-society-of-gene-and-cell-therapy-asgct-2026-annual-meeting</guid>
<pubDate>Tue, 28 Apr 2026 11:01:00 GMT</pubDate>
<description>DURHAM, N.C., April 28, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical data from its PBGENE-DMD program have been accepted for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11-15, 2026, in Boston, Massachusetts. The accepted abstract</description>
</item>
<item>
<title>Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-late-breaking-poster-presentation-for-pbgene-hbv-at-european-association-for-the-study-of-the-liver-congress-2026</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-late-breaking-poster-presentation-for-pbgene-hbv-at-european-association-for-the-study-of-the-liver-congress-2026</guid>
<pubDate>Wed, 22 Apr 2026 11:01:00 GMT</pubDate>
<description>DURHAM, N.C., April 22, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will present new clinical biopsy data from the ongoing Phase 1 ELIMINATE-B trial during a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The ELIMINATE-B trial is evaluating PBGENE-</description>
</item>
<item>
<title>Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-expands-eliminate-b-trial-following-clinical-trial-application-approval-in-two-european-countries</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-expands-eliminate-b-trial-following-clinical-trial-application-approval-in-two-european-countries</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment - DURHAM, N.C.--(BUSINESS WIRE)-- Precision</description>
</item>
<item>
<title>Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 11:01:00 GMT</pubDate>
<description>DURHAM, N.C., April 08, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026.</description>
</item>
<item>
<title>Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-business-update-5</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-business-update-5</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent</description>
</item>
<item>
<title>Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-receives-us-patent-allowances-covering-the-pbgene-hbv-program</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-receives-us-patent-allowances-covering-the-pbgene-hbv-program</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS®</description>
</item>
<item>
<title>Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-presents-preclinical-pbgene-dmd-data-highlighting-durable-dystrophin-expression-and-functional-benefit-at-the-muscular-dystrophy-association-clinical-and-scientific-conference-2026</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-presents-preclinical-pbgene-dmd-data-highlighting-durable-dystrophin-expression-and-functional-benefit-at-the-muscular-dystrophy-association-clinical-and-scientific-conference-2026</guid>
<pubDate>Tue, 10 Mar 2026 11:01:00 GMT</pubDate>
<description>DURHAM, N.C., March 10, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD. The data presentation took place during a poster session at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 currently t</description>
</item>
<item>
<title>Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-receives-fda-fast-track-designation-for-pbgene-dmd-and-announces-duchenne-muscular-dystrophy-investor-event</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-receives-fda-fast-track-designation-for-pbgene-dmd-and-announces-duchenne-muscular-dystrophy-investor-event</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular</description>
</item>
<item>
<title>Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-receives-dollar75m-in-proceeds-from-tg-therapeutics-for-azer-cel-clinical-milestone-in-multiple-sclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-receives-dollar75m-in-proceeds-from-tg-therapeutics-for-azer-cel-clinical-milestone-in-multiple-sclerosis</guid>
<pubDate>Mon, 02 Mar 2026 12:01:00 GMT</pubDate>
<description>DURHAM, N.C., March 02, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (Nasdaq: TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progressi</description>
</item>
<item>
<title>Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-presentation-2026-120100401</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-presentation-2026-120100401</guid>
<pubDate>Wed, 18 Feb 2026 12:01:00 GMT</pubDate>
<description>DURHAM, N.C., February 18, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical study data supporting the potential safety and long-term efficacy of PBGENE-DMD has been selected as a poster presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking place M</description>
</item>
<item>
<title>Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-receives-u-fda-120100224</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-receives-u-fda-120100224</guid>
<pubDate>Wed, 11 Feb 2026 12:01:00 GMT</pubDate>
<description>DURHAM, N.C., February 11, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company received a Study May Proceed notification from the U.S. Food and Drug Administration (FDA). This allows Precision BioSciences to initiate IRB activities and clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical tria</description>
</item>
<item>
<title>Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-sets-strategic-priorities-120100383</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-sets-strategic-priorities-120100383</guid>
<pubDate>Mon, 12 Jan 2026 12:01:00 GMT</pubDate>
<description>DURHAM, N.C., January 12, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today provided a business update and announced strategic priorities for 2026, highlighting recent progress for its two lead programs, upcoming clinical milestones, and a strong financial position supporting execution through key value-inflection points.</description>
</item>
<item>
<title>Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-grant-inducement-120000909</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-grant-inducement-120000909</guid>
<pubDate>Tue, 23 Dec 2025 12:00:00 GMT</pubDate>
<description>DURHAM, N.C., December 23, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on December 9, 2025, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 8,224 restricted stock units ("RSUs") to a new employee under the Precision BioSciences, Inc. 2021 Employment I</description>
</item>
<item>
<title>Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-presentation-clinical-120100988</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-presentation-clinical-120100988</guid>
<pubDate>Wed, 19 Nov 2025 12:01:00 GMT</pubDate>
<description>DURHAM, N.C., November 19, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will deliver an oral presentation at the Hep-DART 2025 meeting, to take place December 7–11, 2025, at the Hilton Hawaiian Village in Honolulu, Hawaii. The presentation will feature data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV.</description>
</item>
<item>
<title>Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-75-million-231200306</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-75-million-231200306</guid>
<pubDate>Mon, 10 Nov 2025 23:12:00 GMT</pubDate>
<description>DURHAM, N.C., November 10, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has agreed to sell by way of an underwritten offering 10,815,000 shares of its common stock and accompanying warrants to purchase up to 5,407,500 shares of common stock at a combined price of $6.14 and, in lieu of common stock</description>
</item>
<item>
<title>Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-presents-breaking-phase-222100781</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-presents-breaking-phase-222100781</guid>
<pubDate>Mon, 10 Nov 2025 22:21:00 GMT</pubDate>
<description>DURHAM, N.C., November 10, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. The presentation includes data from the ongoing ELIMINATE-B Phase 1 study evaluating PBGENE-HBV, a first-in-class in vivo</description>
</item>
<item>
<title>Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-reports-third-quarter-120100584</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-reports-third-quarter-120100584</guid>
<pubDate>Mon, 03 Nov 2025 12:01:00 GMT</pubDate>
<description>DURHAM, N.C., November 03, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.</description>
</item>
<item>
<title>Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-report-third-quarter-110100311</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-report-third-quarter-110100311</guid>
<pubDate>Fri, 31 Oct 2025 11:01:00 GMT</pubDate>
<description>DURHAM, N.C., October 31, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2025 and provide a business update on November 3, 2025.</description>
</item>
<item>
<title>Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-breaking-oral-110100735</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-breaking-oral-110100735</guid>
<pubDate>Tue, 14 Oct 2025 11:01:00 GMT</pubDate>
<description>DURHAM, N.C., October 14, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at the Liver Meeting® 2025. The oral presentation will feature new PBGENE-HBV data from the first two cohorts of the Phase 1 ELIMINATE-B Trial. The Liver Meeting 2025, which is th</description>
</item>
<item>
<title>Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases</title>
<link>https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-publication-nucleic-110100138</link>
<guid isPermaLink="true">https://6ix.com/company/precision-biosciences-inc/news/precision-biosciences-announces-publication-nucleic-110100138</guid>
<pubDate>Thu, 09 Oct 2025 11:01:00 GMT</pubDate>
<description>DURHAM, N.C., October 09, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the publication of a peer-reviewed manuscript titled "High-Efficiency Homology-Directed Insertion into the Genome using the Engineered Homing Endonuclease ARCUS" in the journal Nucleic Acids Research. This publication demonstrates a wide variety of g</description>
</item>
</channel>
</rss>